COX-2 Gastrointestinal Safety Profile Questioned By BMJ Study
This article was originally published in The Pink Sheet Daily
Executive Summary
British Medical Journal researchers were concerned to find increased risk for rofecoxib since lower GI risk “was one of the main justifications for use.”